CRISPR Therapeutics AG (CRSP) Income from Non-Controlling Interests (2015 - 2019)

CRISPR Therapeutics AG has reported Income from Non-Controlling Interests for 5 years, with the latest figure at $14.2 million in Q1 2019.

• Quarterly Income from Non-Controlling Interests rose 13.6% year-over-year to $14.2 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $54.4 million (up 25.93% YoY) and the FY2018 annual result came in at $52.5 million, up 45.03% from the prior year.
• Income from Non-Controlling Interests grew to $14.2 million in Q1 2019 per CRSP's latest filing, from $14.1 million in the prior quarter.
• Over five years, Income from Non-Controlling Interests peaked at $14.2 million in Q1 2019 and troughed at -$16000.0 in Q4 2015.
• A 5-year average of $6.9 million and a median of $9.0 million in 2017 frame the typical range for Income from Non-Controlling Interests.
• The sharpest annual moves came in 2016 and 2017: Income from Non-Controlling Interests sank 1300.0% in 2016, then surged 1150100.0% in 2017.
• Over 5 years, Income from Non-Controlling Interests stood at -$16000.0 in 2015, then soared by 93.75% to -$1000.0 in 2016, then soared by 1150100.0% to $11.5 million in 2017, then gained by 22.61% to $14.1 million in 2018, then rose by 0.71% to $14.2 million in 2019.
• According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $14.2 million, $14.1 million, and $12.6 million for Q1 2019, Q4 2018, and Q3 2018 respectively.